About the Company

Medafor, Inc., was founded in early 1999 to develop and market an innovative breakthrough in hemostatic technology based on engineered biopolymeric microporous particles. By May of 2000, Medafor, Inc., had developed its business plan, long-term strategies and complementary objectives, had hired the key members of its management team, was situated in its new facility in Minneapolis and had completed its first capitalization round. Medafor has applied for and been issued patents protecting its new MPH^® (Microporous Polysaccharide Hemospheres) hemostasis methodology and delivery systems.

In June of 2000, Medafor, Inc., established a medical advisory board of leading medical experts in hematology, wound management, trauma and medical device technology. By late 2000, Medafor completed a second round of financing together with initiating pre-clinical testing of MPH at the Minnesota Medical Research Foundation.

The company is in the process of developing market-specific applications, delivery systems and strategic partnerships for fast-track commercialization.

Patents

Patent #6,060,461
Topically Applied Clotting Material
Issued May 2000

Patent protects 31 method claims relating to enhancing the formation of clots on a wound where blood is present, comprising the steps of applying porous particles having average diameter dimensions of .5 to 1000 microns, and allowing said porous particles to remain in contact with blood while clotting initiates.

Patent #6,992,233
Material Delivery System
Issued January 2006

Patent protects a delivery system for the delivery of flowable medicinal or therapeutic materials which are contained within a securable element and which are released by the removal of a seal which allows the materials to flow from the storage area onto a site selected for treatment.

Medafor's Markets Worldwide

Within the diverse scope of wound management, Medafor, Inc., has developed significant market penetration internationally, primarily with its Arista™AH absorbable surgical hemostat product. Medafor continues to develop new applications and delivery systems and apply for appropriate regulatory clearances as warranted. Currently, Medafor's markets and target markets are:

• Surgical intraoperative procedures including vascular, soft tissue and orthopedic
• Topical vascular wound applications
• ER/EMS topical wound applications
• Military field trauma